Table 4.
Comparison of the clinical features by treatment group
| ST monotherapy | % | Other | % | P value | PTM | % | ATO | % | P value | |
| N=214 | N=119 | N=80 | N=29 | |||||||
| Age (median, IQR) | 71.0 (60.0–77.0) | 71.0 (63.0–77.5) | 0.640 | 71 (65–76) | 73 (59–81) | 0.942 | ||||
| Female | 135 | 63.1 | 75 | 63.0 | 1.000 | 48 | 60.0 | 19 | 65.5 | 0.661 |
| RA and PMR | 30 | 14.0 | 22 | 18.5 | 0.345 | 13 | 16.3 | 7 | 24.1 | 0.403 |
| Non-RA and PMR | 184 | 86.0 | 97 | 81.5 | 67 | 83.8 | 22 | 75.9 | ||
| Primary vasculitis syndrome | 82 | 38.3 | 34 | 28.6 | 0.093 | 25 | 31.3 | 8 | 27.6 | 0.816 |
| Systemic lupus erythematosus | 26 | 12.1 | 23 | 19.3 | 0.106 | 17 | 21.3 | 3 | 10.3 | 0.267 |
| Inflammatory myositis | 36 | 16.8 | 24 | 20.2 | 0.460 | 14 | 17.5 | 7 | 24.1 | 0.425 |
| Systemic sclerosis | 9 | 4.2 | 4 | 3.4 | 0.777 | 1 | 1.3 | 2 | 6.9 | 0.172 |
| Others | 31 | 14.5 | 12 | 10.1 | 0.307 | 10 | 12.5 | 2 | 6.9 | 0.510 |
| Concomitant ILD | 84 | 39.3 | 38 | 31.9 | 0.194 | 26 | 32.5 | 7 | 24.1 | 0.484 |
| Oxygen administration on admission | 49 | 22.9 | 27 | 22.7 | 1.000 | 14 | 17.5 | 10 | 34.5 | 0.071 |
t-test, the Mann-Whitney test, χ2 test and Fisher’s exact test were used when appropriate to compare the groups.
ATO, atovaquone; ILD, interstitial lung disease; PMR, polymyalgia rheumatica; PTM, pentamidine; RA, rheumatoid arthritis.